Neogenomics, Inc.
NEO
$16.05
$0.211.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 201.66M | 186.67M | 190.17M | 187.80M | 181.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 201.66M | 186.67M | 190.17M | 187.80M | 181.33M |
| Cost of Revenue | 109.78M | 105.81M | 106.83M | 107.35M | 104.47M |
| Gross Profit | 91.88M | 80.86M | 83.34M | 80.45M | 76.86M |
| SG&A Expenses | 90.89M | 88.77M | 86.65M | 86.95M | 95.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 211.43M | 204.11M | 202.65M | 202.99M | 209.32M |
| Operating Income | -9.77M | -17.44M | -12.48M | -15.19M | -27.99M |
| Income Before Tax | 1.83M | -17.58M | -12.41M | -26.39M | -45.82M |
| Income Tax Expenses | -412.00K | -472.00K | -2.53M | 740.00K | -724.00K |
| Earnings from Continuing Operations | 2.24M | -17.11M | -9.88M | -27.13M | -45.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.24M | -17.11M | -9.88M | -27.13M | -45.09M |
| EBIT | -9.77M | -17.44M | -12.48M | -15.19M | -27.99M |
| EBITDA | 6.76M | -1.03M | 3.91M | 1.24M | -10.72M |
| EPS Basic | 0.02 | -0.13 | -0.08 | -0.21 | -0.35 |
| Normalized Basic EPS | -0.05 | -0.08 | -0.06 | -0.07 | -0.13 |
| EPS Diluted | 0.02 | -0.13 | -0.08 | -0.21 | -0.35 |
| Normalized Diluted EPS | -0.04 | -0.08 | -0.06 | -0.07 | -0.13 |
| Average Basic Shares Outstanding | 129.63M | 129.17M | 128.65M | 128.42M | 127.95M |
| Average Diluted Shares Outstanding | 130.83M | 129.17M | 128.65M | 128.42M | 127.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |